Comparisons of the pharmacokinetics and the leukopenia and thrombocytopenia grade after administration of irinotecan and 5-fluorouracil in combination to rats

Anticancer Research

Volumn 20, Issue 6 B, 2000, Pages 4235-4242

  Umezawa, T ^a   Kiba, T ^a   Numata, K ^a   Saito, T ^a   Nakaoka, M ^a   Shintani, S ^a   Sekihara, H ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Animal study; Combination therapy; Hematological toxicity; Irinotecan; Pharmacokinetics

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG METABOLISM; DRUG SCREENING; LEUKOPENIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTOPENIA;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ERYTHROCYTES; FLUOROURACIL; INJECTIONS, INTRAVENOUS; LEUKOPENIA; MALE; RATS; THROMBOCYTOPENIA;

EID: 0034483038     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma
2. Aphase 11 study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
3. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
4. Late phase 11 study of CPT-11, topois'omerase I inhibitor, in advanced cervical carcinoma
5. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer
6. Simultaneous administration of CPT-11 and fluorouracil: Alternation of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer
7. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
8. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
9. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
10. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
11. Phase I clinical study of CPT-11. Research group of CPT-11
12. CPT-11 converting carboxylesterase and topoisomerase activities in tumor and normal colon and liver tissues
13. Nonlinear pharmacokinetics of CPT-11 in rats
14. The current status of camptothecin analogues as antitumor agents
15. Topoisomerase I inhibition: A new target or new missiles?
16. CPT-11 (irinotecan) in the treatment of colorectal cancer
17. CPT-11 (irinotecan) and 5-fluorouracil: A promising combination for therapy of colorectal cancer
18. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil and leucovorin in patients with advanced solid tumor
19. Phase I study of a weekly schedule of irinotecan high-dose leucovorin, and infusional fluorouracil as first line chemotherapy in patients with advanced colorectal cancer
20. 14C-SN- 38 to rats
21. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients
22. Phase I and pharmacological studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
23. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11